To determine whether the amount of cyclooxygenase metabolites correlates with the development of lupus nephritis, intrarenal eicosanoid production was measured in autoimmune mice. Disease progression was related to the renal biosynthesis of prostaglandin (PGE2), prostacyclin (6 keto PGFIa), and thromboxane (TXB2) using the MRL-lpr and NZBXNZW F1 hybrid mouse strains with predictably progressive forms of renal disease that mimic the human illness. Mice were evaluated for renal disease by measuring urinary protein excretion and renal immunopathological conditions and these features were related to renal eicosanoid production. These studies show that: (a) intrarenal synthesis of TXB2 increased incrementally in MRL-Ipr and NZBXNZW Fl hybrid mice as renal function deteriorated and renal pathologic events progressed; (b) there were no consistent increases in the levels of two other cyclooxygenase metabolites, PGE2 or 6 keto PGFIa; (c) increased TXB2 production occurred in the renal medulla, cortex, and within enriched preparations of cortical glomeruli; (d) when renal disease was prevented by pharmacologic doses of PGE2, intrarenal TXB2 did not increase; (e) administration of a dose of ibuprofen (9 mg/kg), a cyclooxygenase inhibitor capable of reducing 90% of platelet TXB2 without affecting intrarenal levels, did not retard the progression of renal damage. Taken together, these data indicate that the intrarenal level of TXB2 rises in relation to the severity of murine lupus nephritis. Furthermore, because of the potential deleterious effects of TXA2, enhanced production of this eicosanoid may be an important mediator of renal injury.
Introduction
Autoimmune lupus mice are uniquely valuable for studies of chronic progressive renal injury because their disease is spontaneous and remarkably similar to the human condition. By using both the MRL/MP-lpr (MRL-lpr)' and NZBXNZW F1 hybrid (NZBXW) mice with autoimmune lupus nephritis, it is possible to eliminate unimportant peculiar features unique to a strain and identify common denominators with potential pathogenic relevance.
Arachidonic acid metabolites, most notably prostaglandin Receivedforpublication 29 August 1984 and in revisedform 24 September 1985.
1. Abbreviations used in this paper: KRB, Krebs-Ringer buffer; MRLlpr, MRL/MP-lpr (mice); NZBXW, NZBXNZW F1 hybrid (mice); PGEI, PGE2, and PGF2, prostaglandins El, E2, and F2; 6 keto PGFI., pros- tacyclin; TXA2 and TXB2, thromboxanes A2 and B2.
E2 (PGE2), thromboxane A2 (TXA2), and prostacyclin (6 keto PGF1,), are potent mediators generated during immunologic inflammatory events and are capable of profoundly changing renal hemodynamics (reviewed in References 1-3). Recently, increased renal synthesis ofthromboxane has been demonstrated during the inexorable progression of immune-mediated and nonimmunologic induced models of renal injury (4) (5) (6) (7) (8) . Previous studies demonstrate that supplementing the diet of autoimmune mice with fish oil delays the onset of nephritis (9, 10) , and that there is a concurrent reduction of endogenous renal cyclooxygenase metabolites during this dietary therapy (9) . To assess whether this diet initiated a reduction in one or more renal cyclooxygenase products that might be related to the beneficial effect of a fish oil enriched diet, thromboxane B2 (TXB2), PGE2, and 6 keto PGFI,, the stable hydrolysis product of prostacyclin,
were measured from renal tissue of NZBXW and MRL-lpr mice, which share features of the renal disease, but which differ in their time course and immunologic disturbances (1 1, 12).
Methods
Mice. Male and female MRL-lpr as well as MRL/MP-+ (MRL-++) mice originally obtained from the Jackson Laboratory (Bar Harbor, ME) were bred in our own facility. Female and male MRL-lpr mice were used because disease expression is similar in both sexes. Mating of NZB and NZW in our laboratory produced NZBXW F1 hybrids. In that disease is more predictable and rapidly progressive in female NZBXW mice, studies were limited to this sex. All animals were kept under standard laboratory conditions. Extraction ofcyclooxygenase metabolites. Mice were killed by rapid cervical dislocation, kidneys were excised, and the capsule was gently removed. The kidney was then bisected and the medulla and cortex were rapidly separated by fine dissection. Tissues were immediately moistened with Krebs-Ringer bicarbonate buffer, 22.5 meq, containing KCI, NaCl, NaHCO3, NaH2PO4, and CaCl2 (KRB) at pH 7.2, and 10-30 mg of tissues were finely, uniformly minced with a razor blade and incubated in 2 ml of KRB in a 25-ml flask on a shaker platform in a 5% CO2 incubator at 37°C for 15 min or 30 min. All supernatants were immediately stored at -20°C for PGE2, 6 keto PGFIa, and/or TXB2 analysis.
It was not necessary to extract PGE2, TXB2, or 6 keto PGF1,, from tissues, because cyclooxygenase metabolites accumulate in the medium rather than in the tissues ( 13).
PGE2, TXB2, and 6 keto PGFia assays. PGE2, TXB2, and 6 keto PGFI,, content in supernatant was determined by direct competitive binding radioimmunoassays. Anti-PGE2 serum, kindly provided by Dr. Lawrence Levine (Brandeis University, Waltham, MA) has a 100% crossreactivity with PGE, but only 2.7% with prostaglandin F2 (PGF2) and was used at a final dilution of 1:6,000. Therefore, our results cannot differentiate PGE, and PGE2. However, because PGE2 was used as a standard, we have expressed our results as PGE2 equivalents. Antisera to TXB2, a generous gift of Dr. Perry V. Halushka (Medical University of South Carolina, Charleston, SC), did not cross-react (0.04%) with other arachidonic acid metabolites and was used at a final dilution of 1:50,000 (14) . 6 Keto PGF1, antisera was provided by Dr. Michael Dunn (Case Western Reserve Medical School, Cleveland, OH) and has a crossreactivity as previously described and was used at a 1:15,000 dilution (15) . All Urinary protein. 24 -h urine specimens were collected by placing individual mice in metabolic cages as previously described (16) . Proteinuria was quantitated by the trichloracetic acid method. Based on analysis of female Swiss Webster mice of 2-12 mo of age, urinary protein levels in excess of 1.2 mg/24 h were considered to be pathologic (17) .
Renal morphology. Renal tissues were assessed for morphologic changes by light microscopy using coded slides. Kidney sections were fixed in alcoholic Bouin's fluid and stained with periodic acid-Schiff. Renal histopathologic alterations were graded using a semiquantitative scale ranging from 0 to 4.0 (0, normal; 1, a small increase of cells within the mesangium of the glomerulus; 2, more pronounced increase in the number of mesangial cells and perivascular lymphocytic infiltration in the cortex and medulla; 3, lobular formation ofthe glomerulus, thickening of basement membrane, and prominent numbers of lymphocytes surrounding vessels; 4, glomerular crescent formation, some sclerotic glomeruli, tubular atrophy, and casts and/or vasculitis).
Glomendar preparation. Glomerular enriched fractions were prepared by a modification of the method of Barcelli et al. (18) . Kidneys were removed from mice and placed in phosphate-buffered saline (PBS) (pH 7.4) on ice. After bisecting each kidney, the capsule was removed and the cortex was separated from papilla and medulla. A total of8-10 kidneys was pooled for each experiment. Cortical pieces were gently pressed through a #200 mesh stainless steel sieve (75-,um pore diameter) into 10 ml of PBS. This suspension was forced through a 25-gauge needle and then centrifuged at 1,500 rpm for 5 min and the supernatant was discarded. The pellet was resuspended in 8 ml of PBS and allowed to settle for 30 min. Three quarters ofthe supernatant was aspirated and replaced with fresh PBS. This resuspension and settling step was repeated five to six times. The purity of glomerular preparations was assessed microscopically. Preparations consisted of 60-90% glomeruli with contamination consisting oftubular fragments. Glomerular enriched preparations were suspended in 2 ml of KRB (pH 7.4) at 37°C and incubated for 45 min in 12 X 75-mm siliconized glass tubes with constant agitation at 37°C in a 5% CO2 environment. At the end ofthe incubation, glomeruli were centrifuged at 1,500 rpm for 5 min and the supernatant was removed and stored at -20°C for PGE2 and TXB2 analysis. Glomerular enriched TXB2 PGE2 pellets were resuspended in 2 ml and stored at -20'C until the total protein content was determined by the method of Lowry et al. (19) . In vivo treatments. Groups of MRL-lpr female mice (2 mo of age)
were injected subcutaneously with 5 gg ofa stable PGEI analogue, 15(s)- 15 -methyl PGEI (a gift of Dr. John Pike, The Upjohn Co.), twice daily on 5 days ofthe week and once on Saturday and Sunday. Because previous studies indicated that injecting the vehicle control was similar to uninjected mice, our controls were not injected (16) . Mice were treated for 2 mo and sacrificed at 4 mo of age. Groups of MRL-lpr (2 mo of age) female and male and NZBXW (3 mo of age) female mice were injected daily for 1 wk with ibuprofen (generously supplied by The Upjohn Co.) 8-9 mg/kg, diluted with PBS as previously described (20) . Controls consisted of littermates receiving the vehicle alone.
Statistical analysis ofdata. The Student's t test, Mann-Whitney U test, and linear regression analysis were used to determine significant differences in the data.
Results
Cyclooxygenase metabolites in renal tissue TXB2, PGE2, and 6 keto PGF,a in MRL-lpr mice. There was a dramatic increase in TXB2 levels in renal tissue of MRL-lpr mice during the course of autoimmune disease based on measurements before the onset of lymphadenopathy (2 mo) and after palpable nodes were apparent (4-6 mo). A significant increase in TXB2 synthesis occurred in both the cortex and medulla of older MRL-/pr mice with lymphoproliferation as compared with MRL-++ and 2-mo MRL-lpr animals (P < 0.01, Fig. 1 ). Thus, the increase in TXB2 synthesis was limited to mice expressing products of the lpr gene. Cortical TXB2 levels in older MRL-/pr mice increased fivefold as compared to young mice of the same strain, whereas medullary TXB2 synthesis was at least three times greater in older MRL-lpr as compared with MRL-++ and young MRL-lpr mice. In fact, cortical TXB2 (pg/mg of tissue) in MRL-lpr mice increased progressively 38+2, 90+11, 100±20, and 326±37 at 6, 10, 13, and 20 wk of age, respectively. Similarly, medullary TXB2 (pg/mg of tissue) increased-90±2, 165±3, 280±10, and 415±35 at 6, 10, 13, and 20 wk of age, respectively. In striking contrast to the alteration in TXB2 synthesis in older MRL-lpr mice, PGE2 produc- (Fig. 2) . However, this increase did not appear to be related to disease in that the kidneys ofthese mice were normal between 2 and 4 mo and there was no further increase in this eicosanoid 1 between 4 and 11 mo, when renal disease developed.
Glomerular preparations
In glomerular enriched preparations, the level of TXB2 in MRL-2 lpr mice at 4 mo of age was increased by a factor two to three times above values of age-matched congenic MRL-++ and two to three times above MRL-lpr mice at only 2 mo of age ( Renal pathology and TXB2
TXB2 synthesis increased with the severity of renal pathology in autoimmune mice. A linear regression analysis plotting the degree ofrenal pathology in MRL-1pr mice vs. the level ofcortical TXB2 showed a high degree of correlation (r = 0.87, n = 22, P < 0.01) between these variables (Fig. 5 a) . Similarly, TXB2 levels in the medulla of this strain also increased with the degree of renal pathology (r = 0.78, n = 22, P < 0.01) (Fig. 5 b) . A similar trend occurred in NZBXW mice. There was good correlation of an increase in TXB2 and the severity of pathology in the cortex (r = 0.80, n = 9, P < 0.01) and medulla (r = 0.82, n = 9, P < 0.01) (Fig. 6 ).
Treatments A series of treatment protocols was investigated to determine the relation between renal damage and TXB2 production. Prostaglandin therapy with pharmacologic doses ofPGE. In previous studies, twice-daily injections of pharmacologic doses of PGE1 or PGE2 protected MRL-lpr and NZBXW mice from developing renal disease (16, 21) . As indicated in Table III, treatment of MRL-lpr mice with PGEI modestly reduced TXB2 in the cortex but markedly suppressed production in the medulla as compared with the control group. Treated mice did not become proteinuric nor did they develop renal disease.
Blocking cyclooxygenase metabolites with ibuprofen. As previously reported by our laboratory, daily injections ofibuprofen (8-9 mg/kg) in NZBXW mice did not modify development of renal disease or survival (20) . Although, as previously reported, this dose inhibits 90% of platelet TXB2 production (20) , it did not alter the level of TXB2 in the kidney (Table IV) . There was no substantial decrease in either TXB2 or PGE2 levels in the renal cortex or medulla in the NZBXW or MRL-lpr mice injected with this agent.
Discussion
The present experiments indicate that (a) renal biosynthesis of the specific cyclooxygenase metabolite TXB2 increased in the MRL-lpr and NZBXW mice with spontaneous lupus nephritis; (b) as renal function deteriorated and renal pathologic events progressed, TXB2 increased in the renal medulla, cortex, and cortical glomeruli (60-90% pure); (c) drug therapy and dietary manipulation that prevented renal disease correlated with no elevation in renal TXB2; (d) conversely, a dose of the cyclooxygenase inhibitor, ibuprofen, capable of decreasing platelet but not TXB2 intrarenal synthesis, did not prevent an increase in renal TXB2 or retard the progression of chronic renal injury. Together, these data indicate that increased intrarenal TXB2 synthesis accompanies renal disease in murine lupus nephritis.
Increased intrarenal TXB2 levels have been directly implicated in the relentless progression of immune-mediated and nonimmunologically induced forms of renal injury (4) (5) (6) (7) (8) dicate that augmentation of renal thromboxane biosynthesis is linked to the formation of proteinuria and/or impaired renal hemodynamics. For example, inhibiting renal thromboxane production prevents progressive renal disease with partial renal ablation (6) , reduces proteinuria in adriamycin nephrosis (7), and prevents the decrements in the glomerular filtration rate in immunologically induced nephrotoxic serum nephritis (antiglomerular basement membrane disease) (4 Our results, combined with human studies and data from diverse experimental models of nephritis (4, 7, 8) suggest that elevation of intrarenal TXB2 is a mediator of impaired renal function and a useful indicator of renal injury. To support the role of thromboxane as a modulator of renal injury, studies from our laboratory, as well as other investigators, showed that restricting substrate by feeding a diet deficient in an essential fatty acid (32) or by exclusively limiting lipid to fish oil (9, 10, 33) prevented renal disease and increased survival in autoimmune mice. However, we cannot eliminate the possibility that this beneficial effect was promoted by a reduction in lipoxygenase metabolites. Because both diets reduced the amount of endogenous prostanoids (9) and are theoretically capable of also lowering the lipoxygenase metabolites (34), we cannot exclude the possibility that reductions in 12-hydroxy-5,8,11,13-eicosotetraenoic acid may influence the progression of renal injury. In fact, a recent study suggests that renal function is influenced by TXA2 as well as the sulfidopeptide leukotrienes (35) . At the present time, it is uncertain whether the excess of TXA2 in lupus nephritis is a mediator of renal damage. Although treatment with pharmacologic doses of PGEI prevents increases in renal TXB2 and renal injury, it is possible that the action of PGEI is operating independently of TXB2 suppression. To clarify this point, studies in progress are investigating the effects of direct, specific in vivo inhibition of TXA2 synthesis-in autoimmune mice. Thus, the hemodynamic, immunologic, and inflammatory consequences of altered renal cyclooxygenase metabolism should offer insight into the pathogenesis of renal injury and may provide promising therapeutic possibilities.
